Nevertheless, these studies consistently observed PD-L1 and PD-1 expression in a subset of breast tumors; because PD-L1 expression has previously been shown to be a marker for the efficacy of anti-PD-1 in other tumor types [96], it is possible that PD-L1 expression may be a predictive marker for patients likely to have good responses to a combination of NAC and anti-PD-1. Here, CD274 is linked to breast neoplasm.